Three existing board members do not stand for re-election. Prof. Alfred Buck (former Head of the NeuroPET program at University Hospital Zürich) and Dr. Max Ahnen (COO at Positrigo) are both co-founders and board members since inception and Dr Nicholas Verwilghen (Chief Investment Officer in 1741 Fund Solutions) joined the board during the last investment round. “I want to thank Prof. Buck, Dr. Ahnen and Dr. Verwilghen for their tremendous support as board members as they guided the company successfully through the transition from an R&D focused team to a commercial and customer facing organization,” says Urs Suter, Chairman of the Board of Directors. “We are very fortunate that we can still rely on their continued support and valuable insights.”


About Positrigo:

Positrigo is a pioneer in nuclear medical imaging technologies. Headquartered in Zurich, Switzerland, the medical device company was founded in 2018 as a spin-off of ETH Zurich. Positrigo’s technology, development, clinical testing and commercialization has been supported by various private investors, the Swiss government and the European Innovation Council. NeuroLF – the company’s first device – is an ultra-compact brain Positron Emission Tomography (PET) scanner which has applications in the assessment of causes of dementias, such as Alzheimer’s disease and other brain related disorders. This award-winning product is the first device of its to gain market clearance in the US and EU.

About HealthCap:
HealthCap is a European venture capital firm investing globally in life sciences and has raised nine funds since 1996. HealthCap has backed and built more than 130 companies, taken more than 45 companies public, and completed numerous trade sales. The investment strategy focuses on precision medicine that have the potential to be transformative, change clinical practice, and change the lives of patients suffering from these conditions.

Back to HCB News

Most Read Announcements Homepage